LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Kodu・Aktsiate loetelu・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Avatud

Sektor Tervishoid

1.78 -4.81

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.75

Max

1.99

Põhinäitajad
By Trading Economics
Müük	2M
Aktsiakasum	-0.34
Töötajad	405

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+46.28 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2024

Turustatistika
By TradingEconomics
Turukapital	-2.3M 114M
Eelmine avamishind	6.59
Eelmine sulgemishind	1.78

Uudiste sentiment

By Acuity

34%

66%

93 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

1.54 / 2 Toetus ja vastupanu

Sangamo Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2024, 23:05 UTC

Peamised uudised

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3. nov 2024, 21:12 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3. nov 2024, 20:59 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3. nov 2024, 23:34 UTC

Peamised uudised

Stocks Poised for Lower Open -- Barrons.com

3. nov 2024, 23:16 UTC

Peamised uudised

Tulu

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Working Interest in PNG LNG Now 39.9%

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Receives Final $241 Million Payment From Kumul

3. nov 2024, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3. nov 2024, 20:36 UTC

Tulu

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3. nov 2024, 20:35 UTC

Tulu

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3. nov 2024, 20:35 UTC

Tulu

Westpac Raises Share Buyback Program by A$1 Billion

3. nov 2024, 20:35 UTC

Tulu

Westpac Final Dividend A$0.76/Share

3. nov 2024, 20:33 UTC

Tulu

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3. nov 2024, 20:32 UTC

Tulu

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3. nov 2024, 20:32 UTC

Tulu

Westpac FY Net Profit A$6.99 Billion, Down 3%

3. nov 2024, 18:09 UTC

Peamised uudised

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3. nov 2024, 10:30 UTC

Peamised uudised

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3. nov 2024, 03:00 UTC

Peamised uudised

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2. nov 2024, 13:53 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. nov 2024, 13:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 13:00 UTC

Peamised uudised

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. nov 2024, 12:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:48 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. nov 2024, 12:32 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sangamo Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

46.28% tõus

12 kuu keskmine prognoos

Keskmine 2.75 USD 46.28%

Kõrge 5 USD

Madal 1 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Sangamo Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Sangamo Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.54 / 2Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

93 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

EBITDA

Ärikasum

Ettevõttest Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.